Skip to content

Public FDA record

Z-2686-2024: BD BACTEC MGIT 960 PZA Kit)- IVD qualitative procedure for susceptibility testing of Mycobacterium tuber

Recall record Z-2686-2024 for Becton Dickinson & Co.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-2686-2024
Company in FDA record
Becton Dickinson & Co.
FDA classification date
Aug 16, 2024
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

May intermittently produce falsely resistant results for pyrazinamide (PZA) during susceptibility testing of Mycobacterium tuberculosis isolates.

Source facts

Action
***UPDATE 11/13/2025*** BD Issued an URGENT: Medical Device Correction letters were sent to customers. BD is pleased to announce that we have resumed production of a modified version of the BD BACTEC" MGIT" 960 PZA Kit which includes modified inoculation methods and reduced shelf-life. BD has conducted a thorough review of the performance from all supported inoculum sources using the synthetic raw material and the following change has been implemented for the BD BACTEC" MGIT" 960 PZA Kit. 1. Only inoculum prepared from MGIT tubes 3-5 days post-positivity can be currently supported. 2. Inoculum prepared from MGIT tubes 1-2 days past instrument positivity are currently not supported. 3. Inoculum prepared from solid media are currently not supported. Additionally, the shelf life of the product has been adjusted from 18 months to 13 months to reflect the latest internal supporting data. Clinical users should refer to the updated Instructions for Use (IFU) available at https://www.bd.qarad.eifu.online/hcp. Additional languages will be added as translations are completed. ***UPDATE 8/1/24*** BD issued an Urgent Medical Device Correction Update letter on 8/1/24 as lots were inadvertently missed on the communication sent on 18Jul2024. BD issued URGENT: Medical Device Correction letter on 18Jul2024 via email and mail . Letter states reason for recall, health risk and action to take: 1. Customeers should discard the affected product immediately. 2. There are no recommendations for retesting or reviewing previous patient test results. Actions to be taken by customer: 1. Immediately inspect your inventory for the specific catalog and lot number listed above. Destroy affected product subject to the recall following your institution s process of destruction. 2. Ensure the contents of this notification are read and understood. 3. Share and post this customer letter within your facility network and forward to any customers to whom you may have distributed the product to ensure
Initiated
2024-07-18
Root cause
Under Investigation by firm
Distribution
Worldwide distribution - US Nationwide and the countries of Argentina, Australia, Bangladesh, Belgium, Brunei, Brazil, Canada, China, Costa Rica, Dominican Republic, Guatemala, Guyana, Hong Kong, Haiti, Indonesia, India, Japan, Korea, Myanmar, Macau, Mexico, Malaysia, Nepal, New Zealand, Panama, Peru, Philippines, Pakistan, Singapore, El Salvador, Thailand, Trinidad and Tobago, Taiwan, Vietnam.
Recall number
Z-2686-2024
Recall status
Open, Classified
CDRH record ID
209120
FDA classified
2024-08-16
Recall event number
95023

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗